Quote · The Peter Attia Drive
#403 ‒ Peptides: separating scientific promise from marketing hype
Where this was said
Why peptide claims must be falsifiable and why evidence should precede widespread use
At 52:10 · chapter starts 49:10
For listeners still on the fence, Peter offers one definitive test: what observation would prove a given peptide claim wrong? If the answer is none — if every negative result gets explained away by the wrong dose, bad timing, inferior supplier, or improper stacking — the hypothesis is not falsifiable. And a non-falsifiable hypothesis cannot be corrected by evidence. [1] — Peter Attia "Ask one question of any peptide advocate: what evidence would prove this claim wrong? If every disappointing result gets attributed to wron…" 49:30 This is precisely what conventional drug development enforces: show efficacy in humans, define who benefits, characterize the dose and pharmacokinetics, understand the risks, then decide how it should be used. Adoption follows evidence. The gray-market wellness space has run this order completely backwards — widespread use has preceded the evidence on the assumption that science will eventually catch up. For many of these compounds, it hasn't, and the tell is that the list of claims keeps growing while foundational questions remain open. Peter acknowledges the pharmaceutical industry's failures — but notes those failures happen inside a process built to catch them, one that eliminates 90 to 95% of drug candidates before they ever reach patients. [2] — Peter Attia "A claim which can't fail isn't a scientific claim. And a field that expands rather than narrows its claims over time is moving in the wrong…" 52:10 The episode closes with one of its most memorable lines: a claim that can't fail isn't a scientific claim, and a field that expands rather than narrows its claims over time is doing marketing, not medicine. Hope, he says, deserves a lot more than that.
Ask one question of any peptide advocate: what evidence would prove this claim wrong? If every disappointing result gets attributed to wrong dose, bad supplier, wrong timing, or improper stacking, the hypothesis is not falsifiable — and a non-falsifiable claim is not a scientific claim.
Ninety to 95% of drugs entering clinical trials never reach the market, weeded out by insufficient efficacy, safety concerns, or poor pharmacokinetics — a filter the gray market bypasses entirely.
